Versant Capital Management, Inc Eye Point Pharmaceuticals, Inc. Transaction History
Versant Capital Management, Inc
- $637 Million
- Q2 2025
A detailed history of Versant Capital Management, Inc transactions in Eye Point Pharmaceuticals, Inc. stock. As of the latest transaction made, Versant Capital Management, Inc holds 1,270 shares of EYPT stock, worth $13,271. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,270
Previous 741
71.39%
Holding current value
$13,271
Previous $4,000
175.0%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding EYPT
# of Institutions
166Shares Held
71.7MCall Options Held
232KPut Options Held
207K-
Cormorant Asset Management, LP Boston, MA8.33MShares$87 Million4.79% of portfolio
-
Suvretta Capital Management, LLC New York, NY6.8MShares$71.1 Million1.61% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA6.2MShares$64.8 Million0.07% of portfolio
-
Franklin Resources Inc San Mateo, CA4.15MShares$43.4 Million0.01% of portfolio
-
Federated Hermes, Inc. Pittsburgh, PA4.09MShares$42.7 Million0.05% of portfolio
About EyePoint Pharmaceuticals, Inc.
- Ticker EYPT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 34,072,200
- Market Cap $356M
- Description
- EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intrav...